# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Warrants Exercisable Upon Shareholder Approval With Series A Expiring In 2 Years And Series B In 5 Years, Subject To Interim An...
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.70) per share which beat the analyst consensus estimate of $(2...
Based on an encouraging discussion in the End of Phase 1B/2 Meeting with FDA the Company plans to:Proceed with a pivotal, adapt...
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company ...
– 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of res...
- SEC Filing